CARIBOU'S NOVEL NEXT-GENERATION CRISPR PLATFORM


Associated tags: Cas12a, DNA, RNA, Reindeer, Phenotype, Genome, Rachel Haurwitz, CRISPR, Pharmaceutical industry, Doctor of Philosophy, Patient, FDA, MD, Conference

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, May 30, 2024
Doctor of Philosophy, Rachel Haurwitz, University, CDT, Conference, Bone marrow, CLL, Lymphoma, MD, Medicine, CRISPR, University of Utah, Hematology, Medical College of Wisconsin, Management

BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following event and investor conferences:

Key Points: 
  • BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following event and investor conferences:
    June 2, 2024, CB-010 ANTLER Phase 1 clinical trial data in r/r B-NHL to be shared in a press release at 6:00 pm CDT followed by a live webcast of a discussion with KOLs and management at 7:00 pm CDT.
  • The presenters will include:
    Boyu Hu, MD, director of lymphoma and CLL in the division of hematology and hematologic malignancies, University of Utah
    Mehdi Hamadani, MD, professor of medicine, section chief of hematologic malignancies, Medical College of Wisconsin
    Rachel Haurwitz, PhD, president and chief executive officer, Caribou Biosciences
    Additional participants from Caribou Biosciences include:
    • Jefferies Global Healthcare Conference, New York, NY
    • Goldman Sachs 45th Annual Global Healthcare Conference, Miami, FL

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 7, 2024
Sale, FDA, University, Lupus nephritis, CRISPR, Food, Rachel Haurwitz, Poster, Research, HLA, Reindeer, MD, Doctor of Philosophy, Huntsman Cancer Institute, Amplification, AML, Leukemia, ERL, IND, ASCO, Lymphoma, Patent, Pfizer, CLL, Patient, Society, G&A, MD Anderson Cancer Center, Lupus, Annual general meeting, Investigational New Drug, Pharmaceutical industry

BERKELEY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter 2024 and reviewed recent pipeline progress.

Key Points: 
  • The update will include:
    CB-010 GALLOP: Caribou plans to initiate the GALLOP Phase 1 clinical trial in adult patients with LN and ERL by year-end 2024.
  • CB-011 CaMMouflage: Caribou plans to present initial dose escalation data from the ongoing CaMMouflage Phase 1 clinical trial by year-end 2024.
  • CB-012 AMpLify: Caribou plans to provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.
  • Net loss: Caribou reported a net loss of $41.2 million for the three months ended March 31, 2024, compared to $28.0 million for the same period in 2023.

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
University, CRISPR, Rachel Haurwitz, Abstract (summary), Abstract, Asian literature, Huntsman Cancer Institute, Amplification, Leukemia, ASCO, Lymphoma, CLL, Society, CDT, MD Anderson Cancer Center, Annual general meeting

BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois.

Key Points: 
  • BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois.
  • The ANTLER poster will provide initial dose expansion data.
  • Details of the poster presentation are as follows:
    Presenter: Boyu Hu, MD, assistant professor, director of lymphoma and CLL, division of hematology/hematologic malignancies, Huntsman Cancer Institute at the University of Utah
    The AMpLify poster will provide details on the clinical trial design and objectives.
  • Poster presentations will be available on the Scientific Publications page of Caribou’s website on Monday, June 3, 2024 at 9:00 am CDT.

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Retrieved on: 
Monday, April 15, 2024
CRISPR, Rachel Haurwitz, Abstract, Asian literature, Cas12a, Cell, Gene, Society

BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on the efficient use of Cas12a chRDNA genome-editing technology for in vivo hepatic gene disruption has been accepted for an oral presentation at the 27th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held May 7-11, 2024, in Baltimore, Maryland.

Key Points: 
  • BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on the efficient use of Cas12a chRDNA genome-editing technology for in vivo hepatic gene disruption has been accepted for an oral presentation at the 27th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held May 7-11, 2024, in Baltimore, Maryland.
  • Details of the oral presentation are as follows:
    Accepted abstracts will be available on the ASGCT Annual Meeting website on April 22, 2024 at 4:30 pm ET.
  • The presentation will be available on the Scientific Publications page of Caribou’s website on Friday, May 10, 2024 at 6:00 am ET.

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Retrieved on: 
Thursday, April 4, 2024
Logic, LN, Transplant, Medical College of Wisconsin, Rachel Haurwitz, Infection, Lupus, Risk, Medical college, Patient, Inflammation, Tissue, Autoimmune disease, Standard of care, Doctor of Philosophy, MD, Autoantibody, IND, Congress, HLA, Reindeer, Antibody, CRISPR, Safety, Immune system, Fatigue, FDA, Lupus nephritis, Autoimmunity, Bone marrow, ERL, Medicine, CD19, Food, PD-1, Pharmaceutical industry

BERKELEY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.

Key Points: 
  • The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.
  • CB-010 targets CD19, a protein on the surface of B cells, and has a PD-1 knockout (KO) that reduces CAR-T cell exhaustion.
  • CB-010 holds the potential for deep depletion of disease-causing B cells which could reset the immune system, leading to sustained drug-free remission.
  • Instead, the chRDNA technology allows for precise insertion of the CAR at an intended location within the T cell genome.

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Fast Track, Regenerative Medicine Advanced Therapy, Cancer Immunology Research, Research, CRISPR, Rachel Haurwitz, Doctor of Philosophy, Orphan drug, AML, FDA, Food, Reindeer, AACR, Manuscript, Bone marrow, Amplification, Patent, Patient, ASCT, Asian literature, Acute myeloid leukemia, G&A, IND, Insurance, Pharmaceutical industry

BERKELEY, Calif., March 11, 2024 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the fourth quarter and full year 2023 and reviewed recent pipeline progress.

Key Points: 
  • “For our lead program, CB-010, we plan to present initial dose expansion data and the RP2D in the second quarter of 2024.
  • For our third program, CB-012, we are thrilled to have recently dosed the first patient in the AMpLify trial.
  • In December 2023, Caribou shared regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B clinical meeting.
  • CB-012: Caribou plans to provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.

Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024
Rachel Haurwitz, Poster, Asian literature, Acute myeloid leukemia, CRISPR, AML, AACR

BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinical data from CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML), will be presented as a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10, 2024 in San Diego.

Key Points: 
  • BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinical data from CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML), will be presented as a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10, 2024 in San Diego.
  • Details of the poster presentation are as follows:
    Title: Preclinical evaluation of CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, that exhibits specific and potent cytotoxicity in acute myeloid leukemia (AML) xenograft models
    The poster will be available on the Scientific Publications page of Caribou’s website on Tuesday, April 9, 2024 at 1:30 pm PT.

Caribou Biosciences to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, February 15, 2024
Webcast, Rachel Haurwitz, Reindeer, CRISPR

BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences:

Key Points: 
  • BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences:
    For more information and links to available webcasts, visit the Events page on Caribou’s website.
  • Webcasts will be available on the Caribou website for 30 days after the events.

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

Retrieved on: 
Sunday, January 7, 2024
Gene editing, FDA, Orphan drug, Troy University, Lymphoma, Multiple myeloma, Conference, Mechanics, Amplification, University, Rachel Haurwitz, Air force academy, ASCT, Regenerative Medicine Advanced Therapy, Food, CRISPR, UCB, AAV, Engineering, Patient, Medicine, Fast Track, Westmead Hospital, MD, Doctor of Philosophy, Reindeer, Infrared spectroscopy correlation table, United States Air Force, PST, Organization, AML, Pharmaceutical industry

-- Caribou to present at 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, at 11:15 am PST --

Key Points: 
  • In addition, Caribou highlighted successful execution across its allogeneic CAR-T cell therapy platform over the past year and provided an outlook on multiple clinical catalysts planned for 2024.
  • We are excited to kick off 2024 by welcoming Tim Kelly as Caribou’s chief technology officer,” said Rachel Haurwitz, PhD, Caribou’s president and chief executive officer.
  • Appointed Tim Kelly as Caribou’s chief technology officer, leading the company’s process development and manufacturing organizations.
  • CB-012: Caribou plans to initiate patient enrollment in the AMpLify Phase 1 clinical trial in r/r AML in H1 2024.

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

Retrieved on: 
Tuesday, December 12, 2023
ASCT, Regenerative Medicine Advanced Therapy, Food, FDA, CRISPR, Rachel Haurwitz, Reindeer, Doctor of Philosophy, Randomized controlled trial, Orphan drug, B-cell lymphoma, Patient, Fast Track, Pharmaceutical industry

BERKELEY, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today provided an update based on feedback from the U.S. Food and Drug Administration (FDA) following recent communications and a Type B clinical meeting regarding the CB-010 development program. The company has received the FDA’s feedback on a Phase 3 randomized controlled trial for CB-010, an allogeneic anti-CD19 CAR-T cell therapy in development for patients with second-line relapsed or refractory large B cell lymphoma (r/r LBCL). The FDA stated that Caribou’s proposed comparator arm of platinum-based immunochemotherapy followed by high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) is acceptable.

Key Points: 
  • The FDA stated that Caribou’s proposed comparator arm of platinum-based immunochemotherapy followed by high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) is acceptable.
  • “As our ongoing ANTLER trial progresses, we look forward to engaging again with the FDA ahead of initiating our planned Phase 3 pivotal trial.
  • In Q2 2024, the company plans to report initial dose expansion data from the ANTLER trial and share the recommended Phase 2 dose (RP2D) for CB-010.
  • Caribou plans to initiate a Phase 3 pivotal trial with this RP2D by year-end 2024.